Rosetting Responses of Plasmodium-infected Erythrocytes to Antimalarials
Issued Date
2022-06-01
Resource Type
ISSN
00029637
eISSN
14761645
Scopus ID
2-s2.0-85132787165
Pubmed ID
35405642
Journal Title
American Journal of Tropical Medicine and Hygiene
Volume
106
Issue
6
Start Page
1670
End Page
1674
Rights Holder(s)
SCOPUS
Bibliographic Citation
American Journal of Tropical Medicine and Hygiene Vol.106 No.6 (2022) , 1670-1674
Suggested Citation
Lee W.C., Russell B., Lau Y.L., Nosten F., Renia L. Rosetting Responses of Plasmodium-infected Erythrocytes to Antimalarials. American Journal of Tropical Medicine and Hygiene Vol.106 No.6 (2022) , 1670-1674. 1674. doi:10.4269/ajtmh.21-1229 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/84974
Title
Rosetting Responses of Plasmodium-infected Erythrocytes to Antimalarials
Author(s)
Other Contributor(s)
Abstract
In malaria, rosetting is a phenomenon involving the cytoadherence of uninfected erythrocytes to infected erythrocytes (IRBC) harboring the late erythrocytic stage of Plasmodium spp. Recently, artesunate-stimulated rosetting has been demonstrated to confer a survival advantage to P. falciparum late-stage IRBC. This study investigated the rosetting response of P. falciparum and P. vivax clinical isolates to ex vivo antimalarial treatments. Brief exposure of IRBC to chloroquine, mefloquine, amodiaquine, quinine, and lumefantrine increased the rosetting rates of P. falciparum and P. vivax. Furthermore, the ex vivo combination of artesunate with mefloquine and piperaquine also resulted in increased the rosetting rates. Drug-mediated rosette-stimulation has important implications for the therapeutic failure of rapidly cleared drugs such as artesunate. However, further work is needed to establish the ramifications of increased rosetting rates by drugs with longer half-lifves, such as chloroquine, mefloquine, and piperaquine.